Comparative Pharmacology
Head-to-head clinical analysis: IMIPRAMINE HYDROCHLORIDE versus JANIMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMIPRAMINE HYDROCHLORIDE versus JANIMINE.
IMIPRAMINE HYDROCHLORIDE vs JANIMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin at presynaptic neuronal membranes, increasing their synaptic concentrations. Also has anticholinergic, antihistaminergic, and alpha-1 adrenergic blocking effects.
Imipramine inhibits the reuptake of norepinephrine and serotonin at nerve terminals, potentiating their neurotransmission. It also has anticholinergic and antihistaminergic effects.
Initial 75 mg/day orally in divided doses, increase to 150-200 mg/day; maximum 300 mg/day. For maintenance, 50-150 mg/day orally.
25-50 mg orally 2-4 times daily; maintenance 150 mg/day divided
None Documented
None Documented
Terminal half-life 11-25 hours (mean ~20 h); clinical context: steady-state achieved in ~1 week, dosing adjustment needed in hepatic impairment
5-15 hours (terminal elimination half-life); clinical context: requires twice-daily dosing for steady state.
Renal (70% as metabolites, <5% unchanged), biliary/fecal (30%)
Primarily renal (70-80% as metabolites, 5% unchanged); biliary/fecal (20-30% as metabolites).
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant